GTBP (GT Biopharma Inc) Rentabilitas reged

GTBP (GT Biopharma Inc) - tandha merek perusahaan

GT Biopharma, Inc. (GTBP) gross margins demonstrate pricing power in hematology due to the inelastic demand for leukemia treatments. The development of TriKE bispecific activators enables the targeted destruction of tumors via the patient's NK cells. The current stage of clinical trials for innovative immunotherapeutic agents confirms the company's strategic direction, while 0.00 serves as the final benchmark for this metric.

GTBP Rentabilitas reged GT Biopharma Corp (04.07.2022 - 20.11.2026)

Rincian metrik keuangan lan pasar GT Biopharma, Inc. (GTBP)

- indikator valuasi pasar bisnis:
Pambiji fundamental:GT Biopharma, Inc.
Sampel barang GT Biopharma Corporation

GT Biopharma, Inc. (GTBP) specializes in developing innovative blood cancer immunotherapy methods amidst unstable international supply chains. Gross margin measures the portion of revenue remaining after covering direct production costs, reflecting the efficiency of biomaterial cost management. Analyzing gross profit margins allows investors to assess business resilience to geopolitical risks and avoid purchasing the asset at a valuation peak.